Last reviewed · How we verify

NCT06836427

CMTS0929 for Clostridioides Difficile Infection

Not yet recruiting EARLY_PHASE1 Last updated 20 February 2025
What this trial tests

EARLY_PHASE1 trial testing CMTS0929 in Clostridioides Difficile Infection in 12 participants. Not yet recruiting.

Timeline
20 February 2025
Primary endpoint
31 January 2030
1 July 2030

Quick facts

Lead sponsorThe Second Hospital of Nanjing Medical University
PhaseEARLY_PHASE1
StatusNot yet recruiting
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposetreatment
Enrollment12
Start date20 February 2025
Primary completion31 January 2030
Estimated completion1 July 2030
Sites1 location across China

Drugs / interventions tested

Conditions studied

Sponsor

The Second Hospital of Nanjing Medical University

Who can join

Adults 18 to 75, any sex, with Clostridioides Difficile Infection. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a prospective, open-label, single-arm study to explore the safety and the efficacy of CMTS0929 for patients with Clostridioides difficile infection (CDI).

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of CMTS0929

Trials testing the same drug.

Other recruiting trials for Clostridioides Difficile Infection

Currently open trials in the same condition.

Other The Second Hospital of Nanjing Medical University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06836427.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing